Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?

Table 3 Changes of the lipid metabolism parameters after 3-mo of treatment

Parameter	Patients with T2DM and CAN (n = 81)
	1st group	2nd group	3rd group	4th group	5th group
	(n = 15)	(n = 21)	(n = 12)	(n = 18)	(n = 15)
LDL cholesterol	-8.3 ± 1.4	-12.8 ± 1.9	-7.6 ± 1.0d	-14.2 ± 1.8ah	-33.1 ± 2.4cfil
HDL cholesterol	4.1 ± 1.0	7.1 ± 0.5a	5.7 ± 0.6	7.8 ± 0.7bg	13.9 ± 1.3cfil
ТG	-8.3 ± 1.2	-35.4 ± 2.6c	-13.3 ± 3.4f	-9.3 ± 1.1f	-27.9 ± 3.9chl
TC	-6.7 ± 1.0	-8.2 ± 1.1	-7.1 ± 1.2	-10.7 ± 1.3ag	-27.2 ± 1.9cfil

The results are presented as % change from baseline, (Δ%, Mean ± SEM);

^aP < 0.05,

^bP < 0.01,

^cP < 0.001 - compared to 1^st group;

^dP < 0.05,

^fP < 0.001 - compared to 2^nd group;

^gP < 0.05,

^hP < 0.01,

ⁱP < 0.001 - compared to 3^rd group;

^lP < 0.001 - compared to 4^th group. T2DM: Type 2 diabetes mellitus; CAN: Cardiac autonomic neuropathy; LDL cholesterol: Low density lipoprotein cholesterol; HDL cholesterol: High density lipoprotein cholesterol; ТG: Triglycerides; TC: Total cholesterol.